Patents by Inventor Masuo Kondoh

Masuo Kondoh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200223915
    Abstract: Provided is a novel technique for controlling the blood-brain barrier. An antibody whose epitope is a region within an extracellular domain of Claudin 5 protein.
    Type: Application
    Filed: December 4, 2017
    Publication date: July 16, 2020
    Applicant: OSAKA UNIVERSITY
    Inventors: Yoshiaki OKADA, Masuo KONDOH, Yosuke HASHIMOTO, Keisuke SHIRAKURA, Takefumi DOI, Kiyohito YAGI, Hiroyuki TAKEDA, Tatsuya SAWASAKI
  • Publication number: 20200148765
    Abstract: An object of the present invention is to provide a novel molecule which has high specificity to CLDN-5 and recognizes an extracellular domain of CLDN-5. The object is achieved by an antibody which specifically recognizes a three-dimensional structure or a primary structure of an extracellular domain of a Claudin-5 protein.
    Type: Application
    Filed: April 26, 2018
    Publication date: May 14, 2020
    Applicants: OSAKA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION EHIME UNIVERSITY, FUJIFILM Wako Pure Chemical Corporation
    Inventors: Masuo KONDOH, Kiyohito YAGI, Takefumi DOI, Yoshiaki OKADA, Yosuke HASHIMOTO, Tatsuya SAWASAKI, Hiroyuki TAKEDA, Kohki ENDO, Maki TAMURA
  • Publication number: 20200140542
    Abstract: An object of the present invention is to provide a monoclonal antibody that recognizes an extracellular region of Claudin-2. A monoclonal antibody that specifically binds to an extracellular region of Claudin-2.
    Type: Application
    Filed: December 25, 2017
    Publication date: May 7, 2020
    Applicant: Osaka University
    Inventors: Masuo Kondoh, Kiyohito Yagi, Akihiro Watari, Masayoshi Fukasawa, Minoru Tada, Jun Kunisawa
  • Publication number: 20110165195
    Abstract: A mucosal absorption-enhancing agent is provided that enables oral, nasal or pulmonary administration of peptide drugs whose administration route has heretofore been limited to the injections due to their poor absorption from the mucosa. Specifically, the mucosal absorption of peptide drugs via intestinal, pulmonary or nasal route can be enhanced by allowing the peptide drugs with the C-terminal fragment (C-CPE) of an enterotoxin (CPE) produced by the bacterium Clostridium perfringens of the genus Clostridium, in particular with the C-CPE or its mutants resulting from the substitution and/or deletion of one or several amino acid residues of the C-CPE to act thereon. The composition for mucosal administration of the present invention significantly enhances absorption of peptide drugs, such as human parathyroid hormone hPTH(1-34), human ghrelin and human motilin, through the mucosa of small intestine, lung, nasal cavity and other mucosa.
    Type: Application
    Filed: June 27, 2008
    Publication date: July 7, 2011
    Applicant: Asubio Pharma Co., Ltd
    Inventors: Masuo Kondoh, Hiroshi Uchida, Takeshi Hanada, Masato Hoshino